<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00006240</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000068165</org_study_id>
    <secondary_id>NHLBI-00-H-0156</secondary_id>
    <secondary_id>NCI-171</secondary_id>
    <nct_id>NCT00006240</nct_id>
  </id_info>
  <brief_title>Phenylbutyrate, Dexamethasone, and Sargramostim in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia</brief_title>
  <official_title>A Pilot Study of Phenylbutyrate, Dexamethasone and GM-CSF in Refractory or Relapsed t(8;21) Acute Myeloid Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing&#xD;
      so they stop growing or die. Colony-stimulating factors such as sargramostim may increase the&#xD;
      number of immune cells found in bone marrow or peripheral blood and may help a person's&#xD;
      immune system recover from the side effects of chemotherapy.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of combining phenylbutyrate,&#xD;
      dexamethasone, and sargramostim in treating patients who have refractory or relapsed acute&#xD;
      myeloid leukemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the objective response (complete hematologic remission induction) of&#xD;
           phenylbutyrate, dexamethasone, and sargramostim (GM-CSF) in patients with refractory or&#xD;
           relapsed t(8;21) acute myeloid leukemia.&#xD;
&#xD;
        -  Determine the correlation between histone acetylation, differentiation, and apoptosis in&#xD;
           bone marrow mononuclear cells with response rate in patients treated with this regimen.&#xD;
&#xD;
        -  Determine the overall survival of patients on this regimen.&#xD;
&#xD;
        -  Determine the correlation between histone acetylation, differentiation, and apoptosis in&#xD;
           bone marrow mononuclear cells with pharmacokinetics of this regimen in these patients.&#xD;
&#xD;
        -  Determine the safety and toxicity of this regimen in these patients.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive phenylbutyrate IV continuously and sargramostim (GM-CSF) subcutaneously on&#xD;
      days 1-7 and 15-21. Patients also receive oral dexamethasone on days 1-4 and 15-18. Treatment&#xD;
      continues every 28 days in the absence of disease progression or unacceptable toxicity until&#xD;
      complete hematologic remission is induced. Patients with stable disease at the end of 1&#xD;
      course receive at least 2 additional courses.&#xD;
&#xD;
      Patients are followed twice a week for 3 months, monthly for 1 year, every three months for&#xD;
      the next 4 years, and then annually thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 9-24 patients will be accrued for this study in at least 2&#xD;
      years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2000</start_date>
  <completion_date type="Actual">August 2001</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Leukemia</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>sargramostim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexamethasone</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oral sodium phenylbutyrate</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of t(8;21) acute myeloid leukemia (AML)&#xD;
&#xD;
               -  Failed standard induction chemotherapy or stem cell transplantation (SCT) OR&#xD;
&#xD;
               -  Relapsed after standard induction chemotherapy or SCT OR&#xD;
&#xD;
               -  Refused or not a candidate for SCT or matched allogeneic sibling bone marrow&#xD;
                  transplantation or donor lymphocyte infusion OR&#xD;
&#xD;
               -  Refused of not a candidate for autologous SCT or bone marrow transplantation&#xD;
&#xD;
          -  No CNS leukemia&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  At least 7 days&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  AST or ALT no greater than 3 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Bilirubin no greater than 3 times ULN&#xD;
&#xD;
          -  No hepatic disease that would preclude study&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 2 mg/dL&#xD;
&#xD;
          -  Creatinine clearance at least 60 mL/min&#xD;
&#xD;
          -  No renal disease that would preclude study&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No cardiac disease that would preclude study&#xD;
&#xD;
          -  No New York Heart Association class III or IV heart disease&#xD;
&#xD;
          -  No myocardial infarction within past 8 weeks&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No active infection except cystitis&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  No altered mental status or seizure disorder&#xD;
&#xD;
          -  No other serious disease that would preclude study&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  At least 3 weeks since prior investigational antineoplastic drugs&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Johnson Liu, MD</last_name>
    <role>Study Chair</role>
    <affiliation>National Heart, Lung, and Blood Institute (NHLBI)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892-1182</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Heart, Lung, and Blood Institute</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Medical Center, NY</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Cancer Institute</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213-3489</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2002</verification_date>
  <study_first_submitted>September 11, 2000</study_first_submitted>
  <study_first_submitted_qc>July 25, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 28, 2003</study_first_posted>
  <last_update_submitted>April 27, 2015</last_update_submitted>
  <last_update_submitted_qc>April 27, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 28, 2015</last_update_posted>
  <keyword>recurrent adult acute myeloid leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>4-phenylbutyric acid</mesh_term>
    <mesh_term>Sargramostim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

